The TMB-302 study compared an investigational IM injection of ibalizumab to IV infusion in adults with MDR HIV-1 infection.

Patients in the intramuscular arm received two injections of sotrovimab "in the dorsogluteal muscle," and there was only one grade 3 AE (tenderness), with the rest being grade 1 or 2.

GlaxoSmithKline and Vir Biotechnology have taken a big step toward authorization of an intramuscular formulation of their anti-SARS-CoV-2 antibody sotrovimab.